At a time when many big pharma companies are unreservedly buying into CAR-T therapies, Merck KGaA (MRK: DE) has taken a step away from the assets it has in the space.
The German company has amended the collaboration and license agreement it signed with Intrexon (NYSE: XON) in 2015 to develop and commercialize CAR-T therapies using Intrexon’s proprietary RheoSwitch Therapeutic System and the Sleeping Beauty non-viral gene integration technology.
Merck is now assigning development rights to Intrexon in return for shares of its common stock valued at $150 million, plus a note for another $25 million in stock.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze